Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis.

A post hoc comparison of baseline characteristics between dupilumab-treated patients with or without optimal response in pooled PRIME/PRIME2 showed a trend for more severe disease at baseline in dupilumab-treated patients without optimal response versus optimal responders, including higher proportions of patients with an IGA PN-S score of 4 (35.4% of patients without optimal response vs 27.8% of optimal responders) and a PGIS “severe” score (75.8% vs 68.5%), as well as fewer healed lesions from PAS (≥ 50% healed lesions from PAS in 7.1% vs 13.0% of patients) and higher use of antidepressants (11.1% vs 9.3%) (Supplementary Table 1 of the ESM).

also in 53,322 other papers

Conclusion Dupilumab treatment versus placebo resulted in nominally significant improvements in signs, symptoms, and quality of life in patients with PN without optimal response by week 24, supporting the benefits of continued treatment.

also in 7,732 other papers